Andere Sprachen Wave Life Sciences Ltd.

Aktien

A1436W

SG9999014716

WVE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
5.01 ^USD	-1.38%		+4.59%	-0.79%

23.04.	Wave Life Sciences Ltd. meldet anhaltende Dynamik in der GSK-Kooperation und Fortschritte bei siRNA und RNA-Editing	CI
12.03.	WAVE LIFE SCIENCES LTD. : erhält Kaufen-Rating von Mizuho Securities	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23.04.
Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23.04.
Wave Life Sciences to Present at Upcoming Investor Conferences	27.03.
Sector Update: Health Care Stocks Higher Late Afternoon	06.03.
WAVE Life Sciences Shares Surge After Q4 Beats Estimates	06.03.
Wave Life Sciences: Q4 Earnings Snapshot	06.03.
Wave Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06.03.
Wave Life Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06.03.
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q4 Revenue $29.1M, vs. Street Est of $19.8M	06.03.
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	06.03.
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024	28.02.
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy	27.02.
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones	08.01.
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference	03.01.
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	18.12.
Wave Life Sciences Starts Dosing in Neuromuscular Disorder Study	15.12.
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15.12.
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15.12.
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07.12.
Sector Update: Health Care	07.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Wave Life Sciences Ltd.

Aktien

A1436W

SG9999014716

WVE

Andere Sprachen

Filter